BioSpace News Archive

Business

Noxxon Releases Interim 2017 Results

NOXXON Pharma, a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment, has today released its interim 2017 results for the six months to June 30, 2017.

October 30, 2017

·

7 min read

Business

Facilitating A Drug Discovery Ecosystem Genestack Joins The Milner Therapeutics Institute

Yassin sees increasingly that data needs to be managed across organisational boundaries and between the academic and industry communities, an area where the company has particular strengths.

October 30, 2017

·

5 min read

Genetown

Biogen to Present at the Clinical Trials on Alzheimer’s Disease Conference

Biogen announced today that it will present detailed data from a recently conducted analysis of the long-term extension of its ongoing Phase 1b study of aducanumab at the 10th Clinical Trials on Alzheimer’s Disease Conference meeting in Boston.

October 30, 2017

·

1 min read

Business

Exactech Q3 Revenue $61.4 Million

Diluted earnings per share for the third quarter was $0.20 based on net income of $2.9 million, compared to third quarter 2016 net income of $3.2 million and diluted earnings per share of $0.22.

October 30, 2017

·

6 min read

Business

Orthofix International Reports Third Quarter 2017 Financial Results

Net sales were $105.2 million, diluted earnings per share from continuing operations was $0.18 and adjusted earnings per share from continuing operations was $0.42.

October 30, 2017

·

18 min read

Merck KGaA Release: New Data Analyses at ECTRIMS Highlight Benefit-Risk Profile of Investigational Cladribine Tablets in Relapsing Multiple Sclerosis

Merck KGaA announced new benefit-risk data for investigational Cladribine Tablets, for the treatment of relapsing multiple sclerosis (MS), at MSParis2017 in Paris, France.

October 30, 2017

·

10 min read

Drug Development

Actuate Therapeutics Receives Rare Pediatric Disease Designation for 9-ING-41 for Treatment of Neuroblastoma

The Rare Pediatric Disease Designation of 9-ING for the treatment of pediatric neuroblastoma comes in addition to Orphan Drug Designations previously granted by the FDA for neuroblastoma, and separately,

October 30, 2017

·

3 min read

Deals

PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposal

PDL BioPharma today issued the following statement in response to the Neos Board of Directors’ rejection of PDL’s October 26 proposal to acquire Neos for $10.25 per share in cash.

October 30, 2017

·

2 min read

Business

Theradiag Release: Revenues at the End of September 30, 2017

During the period to September 30, 2017, Theradiag generated consolidated revenues of €6.8 million, up +7% compared with 2016.

October 30, 2017

·

2 min read

Pharnext Announces Acceptance of Late Breaking Abstract at the 10th Clinical Trials on Alzheimer’s Disease Conference

Pharnext announced that new synergy data related to PXT864, the Company’s second lead PLEODRUG in development for the treatment of Alzheimer’s disease (AD), will be presented as a late breaking poster at the 10th Clinical Trials on Alzheimer’s Disease Conference.

October 30, 2017

·

3 min read